

Date: July 26, 2024

**BSE Limited**

Corporate Relationship Dept.,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**Scrip Code: 532039**

Dear Sir/ Ma'am,

**Sub: Submission of Unaudited Financial Results of Zenotech Laboratories Limited (the 'Company') for the quarter ended June 30, 2024 - Outcome of the Board Meeting held today i.e. July 26, 2024**

With reference to the intimation of Board Meeting submitted on July 18, 2024, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. July 26, 2024, which commenced at 4:00 p.m. IST and ended at 5:20 p.m. IST.

The Board has, *inter-alia*, approved Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2024.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2024 along with the Limited Review Report of the Statutory Auditors.

This is for your information and dissemination.

Thanking You,

Yours faithfully,  
For **Zenotech Laboratories Limited**

(Abdul Gafoor Mohammad)  
**Company Secretary & Compliance Officer**  
**ICSI Membership No. A22331**

*Encl: as above*

**Independent Auditor's Review Report on review of Interim Financial Results**

**To the Board of Directors of Zenotech Laboratories Limited**

1. We have reviewed the unaudited financial results ("the Statement") of **Zenotech Laboratories Limited** ("the Company") for the quarter ended 30<sup>th</sup> June 2024, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

2. **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. **Auditor's Responsibility**

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

#### 4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP  
Chartered Accountants  
Firm Registration No. 003990S/S200018



Viswanadh VNSS Kuchi  
Partner  
Membership No. 210789  
Place: Hyderabad  
Date: 26-July-2024  
UDIN: 24210789BKGFFU2090

**ZENOTECH LABORATORIES LIMITED**

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Standalone Unaudited Financial Results for the Quarter ended 30 June 2024

(Rs in lakhs, except share and per equity share data)					
Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		Unaudited	Audited*	Unaudited	Audited
I	Revenue From Operations	889.49	808.96	823.79	3,676.15
II	Other Operating Income	101.77	101.79	101.77	407.16
III	Other Income	33.70	32.60	20.08	100.41
IV	<b>Total Income (I+II+III)</b>	<b>1,024.96</b>	<b>943.35</b>	<b>945.64</b>	<b>4,183.72</b>
V	<b>Expenses</b>				
	a). Cost of materials consumed	7.11	-	-	-
	b). Purchase of Stock-in-Trade	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	d). Employee benefit expenses	295.40	268.08	222.87	946.40
	e). Finance costs	-	-	-	-
	f). Depreciation and amortization expense	172.66	173.33	180.10	708.52
	g). Other Expenses	345.24	364.68	335.97	1,414.66
	<b>Total expenses</b>	<b>820.41</b>	<b>806.09</b>	<b>738.94</b>	<b>3,069.58</b>
VI	<b>Profit/(Loss) before exceptional items and tax (IV-V)</b>	<b>204.55</b>	<b>137.26</b>	<b>206.70</b>	<b>1,114.14</b>
VII	Exceptional items	-	-	-	-
VIII	<b>Profit/(Loss) before tax (VI-VII)</b>	<b>204.55</b>	<b>137.26</b>	<b>206.70</b>	<b>1,114.14</b>
IX	Tax expense				
	a). Current Tax	-	-	-	-
	b). Deferred Tax	75.58	71.31	62.22	284.27
	<b>Total Tax Expense (IX)</b>	<b>75.58</b>	<b>71.31</b>	<b>62.22</b>	<b>284.27</b>
X	<b>Profit/(Loss) for the period (VIII-IX)</b>	<b>128.97</b>	<b>65.95</b>	<b>144.48</b>	<b>829.87</b>
XI	Other Comprehensive Income				
	a). Items that will not be reclassified to Profit or Loss				
	Re - measurement of the defined benefit obligations	(0.96)	(7.19)	1.12	(3.84)
	b). Items that will be reclassified to Profit or Loss	-	-	-	-
	Less: Income Tax	0.28	1.85	(0.28)	1.12
	<b>Total Other Comprehensive Income (a+b)</b>	<b>(0.68)</b>	<b>(5.34)</b>	<b>0.84</b>	<b>(2.72)</b>
XII	<b>Total Comprehensive Income for the period (X+/-XI)</b>	<b>128.29</b>	<b>60.61</b>	<b>145.33</b>	<b>827.15</b>
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e.Other equity				2,951.10
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)				
	a). Basic	0.21	0.11	0.24	1.36
	a) Diluted	0.21	0.11	0.24	1.36

\* The figures for the quarter ended March 31, 2024 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.

See accompanying notes to the financial results



**Notes:**

1. The above financial results for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 26<sup>th</sup> July, 2024 and have undergone a 'limited review' by the Statutory Auditors of the Company.
2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8<sup>th</sup> June, 2022 and Long Form Standing certificate dated 15<sup>th</sup> June, 2022 respectively, received from the concerned authorities. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence no longer CFS is applicable.
5. The Company received winding up order for Zenotech Laboratories Nigeria Limited during FY: 2019-20. However, related filings with RBI is pending.
6. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
7. The Company has only one segment, i.e. Pharmaceuticals.
8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman of the Board meeting  
DIN: 01219312

Place: Chandigarh  
Date: 26-July-2024